Ms. magazine  -- more than a magazine a movement

SIGN UP FOR MS. DIGEST, JOBS, NEWS AND ALERTS

FEMINIST WIRE NEWSBRIEFS

ABOUT
SEE CURRENT ISSUE
SHOP MS. STORE
MS. IN THE CLASSROOM
FEMINIST DAILY WIRE
FEMINIST RESOURCES
PRESS
JOBS AT MS.
READ BACK ISSUES
CONTACT
RSS (XML)
 
feminist wire | daily newsbriefs

July-24-13

Teva Pharmaceuticals Gets Exclusive Rights to OTC Emergency Contraception

The US Food and Drug Administration has given Teva Pharmaceuticals, the makers of brand name emergency contraception pill Plan B One-Step, exclusive rights to sell their product on store shelves without age restrictions for three years. Generic versions of pill will remain behind the counter and only be available to those 17 years of age or older.

Plan B One-Step costs approximately $50, whereas generic versions cost between $35 and $40. However, with the exclusive rights for Teva, the cost-effective versions will still be denied to young girls or those who do not have government issued identification, creating a barrier for many women and girls. Teva has promised to not increase the price of the drug while it has market exclusivity.

Janet Crepps, senior counsel at the Center for Reproductive Rights, told reporters "The FDA should have left open the option for all generic and potentially more affordable brands of emergency contraception to be made widely available, without delay."

The FDA cites clinical data Teva submitted in June that showed that Plan B One-Step could be safely taken by young teens as justification for exclusivity. Former FDA assistant commissioner for women's health, Susan Wood, told the Boston Globe, "The rationale behind exclusivity is that if a company does essential new research to get their product approved over-the-counter, they should get protection from generics for a little bit longer. But the data Teva was asked to collect wasn't actually essential, and now we're left in a confusing situation that makes it more expensive for women to get full access to emergency contraception."

In April, US District Judge Edward Korman ruled that the FDA must make single-pill versions of the morning-after pill available to women and girls of all ages and that it be made over the counter. Korman did not mandate that the restrictions be lifted from the two-pill versions. In June, the Obama Administration announced that it would not challenge the US Second Circuit Court's upholding of Korman's ruling.

Media Resources: Boston Globe 7/24/2013; ThinkProgress 7/23/2013; Feminist Newswire 6/11/2013, 6/5/2013, 4/5/2013


© Feminist Majority Foundation, publisher of Ms. magazine

If you liked this story, consider making a tax-deductible donation to support Ms. magazine.

 

 

Send to a Friend
Their
Your
Comments
(optional)


More Feminist News

12/18/2014 New Jersey is Inching Closer to Mandatory Paid Sick Leave Statewide - The Assembly Budget Committee of the New Jersey state legislature approved a paid sick leave bill Monday by a 6-4 vote. If the bill is passed, New Jersey workers will earn one hour of paid sick leave for every 30 hours worked. . . .
 
12/18/2014 American Apparel Hired Its First-Ever Woman Chief Executive to Replace Dov Charney - Six months after retail store American Apparel fired its chief executive and founder Dov Charney, the company has hired retail executive Paula Schneider as a replacement. Schneider, who will become American Apparel's first female chief executive, will take over the position as of January 5. Charney had led American Apparel since 1998 and became well-known from American Apparel's sexist advertising and from several sexual harassment lawsuits and sexual assault accusations against him by former employees. . . .
 
12/18/2014 Obama's Judicial Appointments Most Diverse in History - Congress came to a close on Tuesday night with the Senate confirmation of 12 new federal judges and 12 executive appointments - including Vivek Murthy as Surgeon General, Sarah Saldana as head of Immigration and Customs Enforcement, and Tony Blinken as deputy Secretary of State. . . .